



## BIOVERSYS APPOINTS MEDICAL DIRECTOR AND HEAD OF CMC

Basel, Switzerland. June 30, 2021, 9am CEST

### BioVersys adds experienced personnel to key management positions

BioVersys AG is further strengthening its management team with the appointments of Dr. Stephan Amrein as Head of CMC and Dr. Isabelle Andrieux-Meyer as Medical Director.

Stephan joins BioVersys with 17 years of experience in pharmaceutical product development. Most recently, Stephan worked at Novartis in various roles in Supply Chain, Technical Research & Development, and Global Program Management. During his tenure at Novartis, Stephan supported technical development, NDA submissions, and the launch of products like Entresto, Jadenu, Tabrecta. Prior to Novartis, Stephan worked in technical development roles at Acino and Siegfried.

Isabelle joins BioVersys with 25 years experience in neglected infectious diseases management, and research and development. Most recently, as Head of Clinical Development with Drugs for Neglected Diseases initiative (DNDi), Isabelle contributed to the clinical development, regulatory submission and launch of ravidasvir, and a paediatric fixed dose combination of lopinavir/ritonavir/abacavir/lamivudine. Prior to DNDi, Isabelle worked with Médecins Sans Frontières as Medical Director and Operations Project Manager, and at the Geneva University Hospital as physician in the infectious diseases consultations.

**Dr. Marc Gitzinger, CEO and founder of BioVersys:** “We are very pleased that Isabelle and Stephan have chosen to join BioVersys as we rapidly progress our clinical pipeline and move BioVersys into a stronger position to deliver on our corporate objectives. Antimicrobial resistance is a silent and growing threat that can affect anyone, of any age, and at any time. It is important that we deliver novel antimicrobial therapies to healthcare systems, to ensure they are able to continue to provide the medical care we have become used to over the last century.”

“I am thrilled to join the BioVersys team,” said **Stephan**. “While antimicrobial resistance is emerging as a top priority health threat, I am at BioVersys to help develop innovative medicines to fight against multi-resistant bacterial infections, and ultimately to save lives of patients.”

**Isabelle** said: “My experience has shown me the devastating effect that infectious diseases have on so many patients around the world. Antimicrobial resistance has resulted in the majority of our current AMR therapies becoming obsolete. I’m determined to help make a difference by joining the BioVersys team to develop effective and much needed novel antibacterial therapies against the very global threat of AMR.”



## About BioVersys

BioVersys AG is a privately-owned clinical stage Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance (AMR) and targeted microbiome modulation. With the company's award-winning TRIC technology we can overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria, towards the identification of new treatment options in the antimicrobial and microbiome fields. By this means, BioVersys addresses the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. Our most advanced research and development programmes address nosocomial infections of *Acinetobacter baumannii* (BV100, Phase 1), and tuberculosis (BVL-GSK098, Phase 1) in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille. BioVersys is located in the Technologiepark in the thriving biotech hub of Basel.

## BioVersys contacts

**Alina Lundin**, Executive Assistant to CEO, Tel. +41 61 633 22 50; Mail: [info@bioversys.com](mailto:info@bioversys.com)

Website: [www.bioversys.com](http://www.bioversys.com).

